Resistant Haemophilus influenzae in community-acquired respiratory tract infections: A role for cefixime

International Journal of Antimicrobial Agents

Volumn 21, Issue 6, 2003, Pages 501-509

  Verhoef, Jan ^a   Gillissen, A ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Robert Koch Klinik   (Germany)

Author keywords

Cefixime; H. influenzae; Resistance; RTI; Lactamase

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAMASE; CEFACLOR; CEFIXIME; CEFUROXIME; CLARITHROMYCIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CELL ADHESION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMMUNICABLE DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SENSITIVITY; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; INFECTION CONTROL; LOWER RESPIRATORY TRACT INFECTION; MORAXELLA CATARRHALIS; NONHUMAN; OPSONIZATION; OTITIS MEDIA; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SINUSITIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 0038182540     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00095-5     Document Type: Review

References (47)

1. Gwaltney J.M. Jr. Acute community-acquired sinusitis. Clin. Infect. Dis. 23:1996;1209-1223.
2. Sethi S., Murphy T.F. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin. Microbiol. Rev. 14:2001;336-363.
3. Bandi V., Apicella M.A., Mason E., et al. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am. J. Respir. Crit. Care Med. 164:2001;2114-2119.
4. Gehanno P., Panajotopoulos A., Barry B., et al. Microbiology of otitis media in the Paris, France, area from 1987 to 1997. Pediatr. Infect. Dis. J. 20:2001;570-573.
5. Crook G., Wilson R., Kroll S., et al. Opsonic requirements and interaction of Haemophilus influenzae with polymorphonuclear neutrophil leukocytes studied by luminol-enhanced chemiluminescence. Microb. Pathog. 7:1989;101-110.
6. LeVine A.M., Whitsett J.A., Gwozdz J.A., et al. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J. Immunol. 165:2000;934-940.
7. Tino M.J., Wright J.R. Surfactant protein A stimulates phagocytosis of specific pulmonary pathogens by alveolar macrophages. Am. J. Physiol. 270:1996;L677-L688.
8. McNeely T.B., Coonrod J.D. Aggregation and opsonization of type A but not type B Haemophilus influenzae by surfactant protein A. Am. J. Respir. Cell. Mol. Biol. 11:1994;114-122.
9. Noel G.J., Brittingham A., Granato A.A., Mosser D.M. Effect of amplification of the Cap b locus on complement-mediated bacteriolysis and opsonization of type b Haemophilus influenzae. Infect. Immun. 64:1996;4769-4775.
10. Shuto T., Xu H., Wang B., et al. Activation of NF-kappa B by nontypeable Haemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha/beta-I kappa B alpha and MKK 3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc. Natl. Acad. Sci. USA. 98:2001;8774-8779.
11. Williams J.D., Moosdeen F. Antibiotic resistance in Haemophilus influenzae: epidemiology, mechanisms and therapeutic possibilities. Rev. Infect. Dis. 8:(Suppl. 5):1986;S555-S561.
12. Reid A.J., Simpson I.N., Harper P.B., Amyes S.G. Ampicillin resistance in Haemophilus influenzae: identification of resistance mechanisms. J. Antimicrob. Chemother. 20:1987;645-656.
13. Jorgensen J.H. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin. Infect. Dis. 14:1992;1119-1123.
14. Jacobs M.R. Increasing antibiotic resistance among otitis media pathogens and their susceptibility to oral agents based on pharmacodynamic parameters. Pediatr. Infect. Dis. J. 19:(Suppl. 5):2000;S47-S55.
15. Richard M.P., Aguado A.G., Mattina R., Marre R. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. Surveillance Programme of Antibiotic Resistance. J. Antimicrob. Chemother. 41:1998;207-214.
16. Doern G.V., Jones R.N., Pfaller M.A., Kugler K. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob. Agents. Chemother. 43:1999;385-389.
17. Felmingham D., Grüneberg R.N. The Alexander Project 1996-97: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J. Antimicrob. Chemother. 45:2000;191-203.
18. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Eighth Informational Supplement M100-S8. Wayne, PA, USA, 1998.
19. Penttila M., Svolainen S., Kiukaanniemi H., Forsblom B., Jousimies-Somer H. Bacterial findings in acute-maxillary sinusitis - European study. Acta Otolaryngol. Suppl. 529:1997;165-168.
20. Blumer J.L. Pharmacokinetics and pharmacodynamics of new and old antimicrobial agents for acute otitis media. Pediatr. Infect. Dis. J. 17:1998;1070-1075.
21. Craig W.A. Have we reached the point of no return? The hidden impact of antimicrobial resistance in respiratory tract infection. Introduction. Respir. Med. 95:(Suppl. A):2001;S2-S4.
22. Neu H.C. Oral β-lactam antibiotics from 1960 to 1994. Infect. Dis. Clin. Pract. 4:(Suppl. 2):1995;S39-S49.
23. Davis J., Watson J., Haselby R., Nelson B., Johnson D. Comparison of once-daily and twice-daily cefixime regimens with amoxicillin in the treatment of acute upper respiratory tract infections. Curr. Ther. Res. 48:1990;829-840.
24. Peyramond D., Tigaud S., Bremard-Oury C., Scheimberg A. Multicenter comparative trial of cefixime and phenoxymethylpenicillin for group A beta-hemolytic streptococcal tonsillitis. Curr. Ther. Res. 55:(Suppl. 5):1994;14-21.
25. Glasziou P.P., Del Mar C.B., Hayem M., Sanders S.L. Antibiotics for acute otitis media in children. Cochrane Database Syst. Rev. 4:2000;CD000219.
26. Gooch W.M. 3rd, Philips A., Rhoades R., Rosenberg R., Schaten R., Starobin S. Comparison of the efficacy, safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. Pediatr. Infect. Dis. J. 16:(Suppl. 2):1997;S21-S24.
27. Wu D.H. Efficacy and tolerability of cefixime in otitis media. A multicentre study in over 25 000 children. Drugs. 42:(Suppl. 4):1991;30-32.
28. Kaplan B., Wandstrat T.L., Cunningham J.R. Overall cost in the treatment of otitis media. Pediatr. Infect. Dis. J. 16:(Suppl. 2):1997;S9-S11.
29. Lanza D.C., Kennedy D.W. Adult rhinosinusitis defined. Otolaryngol. Head Neck Surg. 117:(3 Pt 2):1997;S1-S7.
30. Lund V.J. Rhinosinusitis. Br. J. Hosp. Med. 57:1997;308-312.
31. Craig W.A. Antimicrobial resistance issues of the future. Diagn. Microbiol. Infect. Dis. 25:1996;213-217.
32. Edelstein D.R., Avner S.E., Chow J.M., et al. Once-a-day therapy for sinusitis: a comparison study of cefixime and amoxicillin. Laryngoscope. 103:(1 Pt 1):1993;33-41.
33. Monso E., Ruiz J., Rosell A., et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am. J. Respir. Crit. Care Med. 153:(4 Pt 1):1995;1316-1320.
34. Soler N., Torres A., Ewig S., et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am. J. Respir. Crit. Care Med. 157:(5 Pt 1):1998;1498-1505.
35. Eller J., Ede A., Schaberg T., Niederman M.S., Mauch H., Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 113:1998;1542-1548.
36. Iqbal A., Schloss S., George D., Isonaka S. Worldwide guidelines for chronic obstructive pulmonary disease: a comparison of diagnosis and treatment recommendations. Respirology. 7:2002;233-239.
37. Pauwels R. Global initiative for chronic obstructive lung diseases (GOLD): time to act. Eur. Respir. J. 18:2001;901-902.
38. Stockley R.A., Bayley D., Hill S.L., Hill A.T., Crooks S.W., Campbell E.J. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax. 56:2001;366-372.
39. Vogel F., Scholz H., al-Nawas B., et al. Rational use of oral antibiotics. Findings of an expert commission of the Paul Ehrlich Society for Chemotherapy (in German). Med. Monatsschr. Pharm. 25:2002;193-204.
40. Neu H.C., Chick T.W. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest. 104:1993;1393-1399.
41. Amir J., Harel L., Eidlitz-Markus T., Varsano I. Comparative evaluation of cefixime versus amoxicillin-clavulanate following ceftriaxone therapy of pneumonia. Clin. Pediatr. (Philadelphia). 35:1996;629-633.
42. Lorenz J. Comparison of 5-day and 10-day cefixime in the treatment of acute exacerbations of chronic bronchitis. Chemotherapy. 44:(Suppl 1):1998;15-18.
43. Crooks S.W., Bayley D.L., Hill S.L., Stockley R.A. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur. Respir. J. 15:2000;274-280.
44. Agusti A.G.N. Surrogate markers in chronic obstructive pulmonary disease. Eur. Respir. Rev. 74:2000;365-369.
45. Becher G, Gillissen A, Rothe M. Oral cefixime therapy reduces bacterial load and inflammatory indices in patients with infection-induced exacerbations of severe chronic obstructive pulmonary disease. (Abstract); Fourth European Congress of Chemotherapy and Infection. Paris, 2002.
46. Gibson P.G., Henry R.L., Thomas P. Non-invasive assessment of airway inflammation in children: induced sputum, exhaled nitric oxide, and breath condensate. Eur. Respir. J. 16:2000;1008-1015.
47. Gessner C., Kuhn H., Seyfarth H.J., et al. Factors influencing breath condensate volume. Pneumologie. 55:2001;414-419.